Affiliated with a Castle Connolly Top Hospital
Who is Dr. Koong, Radiation Oncologist in Houston, TX?
Dr. Albert Koong, MD, PHD is a Radiation Oncologist, who primarily practices in Houston, TX with 2 additional practice locations. He is board certified. Dr. Koong completed his residency at Stanford University School of Medicine. Dr. Koong is fluent in English and Chinese, and is currently seeing new patients. Dr. Koong’s practice accepts Medicare, Aetna, Cigna, UnitedHealthcare and other major insurance plans. To book an appointment or to confirm insurance options, please call Dr. Koong’s office at (713) 792-6161.
What are Areas of Expertise for Dr. Koong?
Dr. Albert Koong, MD, PHD is a highly-rated, board-certified Radiation Oncologist known for expertly diagnosing, treating, and managing a wide array of related conditions and procedures. Utilizing the latest medical advancements and evidence-based practices, Dr. Koong empowers patients to confidently navigate their health journey, specializing in Gastrointestinal Cancer, Liver Cancer, Pancreatic Cancer, and comprehensive wellness support. Serving the Houston, TX community, Dr. Koong is dedicated to enhancing lives through expert, patient-centered care.
Where did Dr. Koong go to medical school and complete their residency?
Residency: Stanford University School of Medicine
Is Dr. Koong board certified as a Radiation Oncologist?
Yes, Dr. Albert Koong, MD, PHD is board certified by the American Board of Radiology since 2001
What languages does Dr. Koong speak?
Dr. Koong and their clinical team can communicate with patients in the following languages:
Chinese
English
What procedures does a Radiation Oncologist like Dr. Koong typically perform?
As a Radiation Oncologist, procedures performed by Dr. Albert Koong may include:
- Abdominal Aortic Aneurysm (AAA) Screening
- Abdominal Imaging
- Abdominal Radiology Consultation
- Angiography
- Arthrography
- Barium Swallow
- Bone Biopsy
- Bone Density Measurement / DXA Scan
Please contact Dr. Koong's office directly to confirm care for your specific procedure, for more information, or to schedule a consultation.
Does Dr. Koong accept my insurance?
Dr. Koong accepts most major insurance plans. Important: Please call our office at (713) 792-6161 before your appointment to verify that your specific plan and network are accepted.
What insurance plans does Dr. Koong accept in Houston, TX?
Dr. Koong in Houston, TX accepts plans from many carriers. While this list is updated regularly, it is not a guarantee of coverage.
Top Insurances
Aetna
Blue Cross Blue Shield
Blue Cross Blue Shield of Illinois
Blue Cross Blue Shield of Michigan
Capital Blue Cross
Cigna
CMS
Elevance Health Inc. (formerly Anthem)
Harvard Pilgrim
Medicare
View All Insurances
Where is Dr. Koong's office located?
Recognitions
Publications
X box-binding protein 1 regulates angiogenesis in human pancreatic adenocarcinomas.
, 2009
XBP-1 regulates angiogenesis in human pancreatic adenocarcinomas
, 2009
Multiplexed protein detection by proximity ligation for cancer biomarker validation
, 2007
Connective tissue growth factor
, 2006
Galectin-1: A link between tumor hypoxia and tumor immune privilege
, 2005
Phase I study of stereotactic radiosurgery in patients with locally advanced pancreatic cancer
, 2004
Stereotactic Body Radiotherapy in the Treatment of Pancreatic Cancer
, 2014
Safety of (90)y radioembolization in patients who have undergone previous exterl beam radiation
, 2013
A novel aldehyde dehydrogese-3 activator
, 2013
Seventh Edition (2010) of the AJCC
, 2013
Dosimetric alysis of organs at risk during expiratory gating
, 2013
Chemoradiotherapy Before and After Surgery for Locally Advanced Esophageal Cancer
Metabolic Tumor Volume Predicts Disease Progression
, 2013
Intrafraction Verification of Gated RapidArc by Using Beam-Level Kilovoltage X-Ray Images
, 2012
BRAF-mutated, Microsatellite-stable Adenocarcinoma of the Proximal Colon
, 2012
Quantitation of Human Papillomavirus D in Plasma of Oropharyngeal Carcinoma Patients
, 2012
A Novel Aldehyde Dehydrogese-3 Activator Leads to Adult Salivary Stem Cell Enrichment In Vivo
, 2011
Stereotactic Body Radiotherapy for Colorectal Liver Metastases A Pooled Alysis
, 2011
Intensity-Modulated Radiation Therapy Versus Conventiol Radiation Therapy for Squamous Cell
, 2011
Unfolded Protein Response Regulation in Keloid Cells
, 2011
Stereotactic Body Radiation Therapy for Gastrointestil Maligncies
, 2011
A DOSIMETRIC MODEL OF DUODEL TOXICITY AFTER STEREOTACTIC BODY RADIOTHERAPY FOR PANCREATIC CANCER
, 2010
Comparison of Intensity-Modulated Radiotherapy
, 2010
(18)FLUORODEOXYGLUCOSE PET IS PROGNOSTIC OF PROGRESSION
, 2010
Circulating miR-210 as a Novel Hypoxia Marker in Pancreatic Cancer
, 2010
EUS-guided gold fiducial insertion for image-guided radiation therapy of pancreatic cancer
, 2010
INTERFRACTIOL UNCERTAINTY IN THE TREATMENT OF PANCREATIC CANCER WITH RADIATION
, 2010
Identification of a biomarker panel using a multiplex proximity ligation
, 2009
Pancreatic Tumor Motion on a Single Planning 4D
, 2009
Treatment of Esophageal Cancer Based on Histology A Surveillance Epidemiology
, 2009
A Primer on Image-guided Radiation Therapy for the Interventiol Radiologist
, 2009
Impaired interferon sigling is a common immune defect in human cancer
, 2009
THE RELATIONSHIP BETWEEN HUMAN PAPILLOMAVIRUS STATUS AND OTHER MOLECULAR PROGNOSTIC MARKERS IN HEAD
, 2009
Safety and Efficacy of Percutaneous Fiducial Marker Implantation for Image-guided Radiation Therapy
, 2009
Gemcitabine chemotherapy
, 2008
In vivo H-1 magnetic resonce spectroscopy of lactate in patients with Stage IV head
, 2008
High-dose single-fraction radiotherapy: Exploiting a new biology?
, 2008
Initial evaluation of F-18-fluorothymidine (FLT) PET/CT scanning for primary pancreatic cancer
, 2008
Automated contour mapping with a regiol deformable model
, 2008
Tissue effects after stereotactic body radiotherapy using cyberknife
, 2008
Expression and prognostic significance of a panel of tissue hypoxia markers in head-and
, 2007
Quantitative PET of EGFR expression in xenograft-bearing mice using Cu-64-labeled cetuximab
, 2007
Evaluation of patterns of failure
, 2007
Plasma osteopontin is an independent prognostic marker for head and neck cancers
, 2006
Results of a phase I dose-escalation study using single
, 2006
Four-dimensiol cone-beam computed tomography using an on-board imager
, 2006
An evaluation of tumor oxygetion
, 2006
Identification of mitogen
, 2005
Radiation dose reduction in four-dimensiol computed tomography
, 2005
Phase II study to assess the efficacy of conventiolly fractioted radiotherapy followed by a
, 2005
A noninvasive approach for assessing tumor hypoxia in xenografts
, 2005
Phase II double-blind r
, 2004
Improved local control with stereotactic radiosurgical boost
, 2003
Comparison of the comet assay
, 2003
Phase II trial of preoperative 3D conformal radiotherapy, protracted venous infusion 5-fluorouracil
, 2003
Estimating D repair by sequential evaluation of head
, 2002
HYPOXIC ACTIVATION OF NUCLEAR FACTOR-KAPPA
, 1994
MODULATION OF POTASSIUM CHANNELS BY PROTEIN-TYROSINE KISE INHIBITORS
, 1994
ACTIVATORS OF PROTEIN-KISE
, 1994
ALYSIS OF HSF-1 PHOSPHORYLATION IN A549 CELLS TREATED WITH A VARIETY OF STRESSES
, 1994
THE REGULATION OF GRP78 AND MESSENGER-R LEVELS BY HYPOXIA IS MODULATED BY PROTEIN
, 1994
INCREASED CYTOTOXICITY OF CHRONIC HYPOXIC CELLS BY MOLECULAR INHIBITION OF GRP78 INDUCTION
, 1994
ACTIVATION OF POTASSIUM CHANNELS BY HYPOXIA AND REOXYGETION IN THE HUMAN LUNG ADENOCARCINOMA CELL
, 1993
POTASSIUM-CHANNEL ACTIVATION IN RESPONSE TO LOW
, 1993
ACTIVATION OF THE HEAT-SHOCK TRANSCRIPTION FACTOR BY HYPOXIA IN NORMAL AND TUMOR
, 1992
THE INFLUENCE OF CHRONIC ANEMIA ON THE RADIOSENSITIVITY OF 2 MOUSE-TUMORS
Cost-effectiveness of modern radiotherapy techniques in locally advanced pancreatic cancer
, 2012
Identification of an Ire1alpha endonucle
, 2011
Imaging the Unfolded Protein Response
, 2010
X box-binding protein 1 regulates angiogenesis in human pancreatic adenocarcinomas.
, 2009
XBP-1 regulates angiogenesis in human pancreatic adenocarcinomas
, 2009
Stereotactic Radiotherapy for Unresectable Adenocarcinoma of the Pancreas
, 2009
The Role of Tumor Cell-Derived Connective Tissue Growth Factor (CTGF
, 2009
Hypoxia-Induced Lysyl Oxidase Is a Critical Mediator of Bone Marrow Cell Recruitment to Form the
, 2009
Multiplexed protein detection by proximity ligation for cancer biomarker validation
, 2007
Connective tissue growth factor
, 2006
Galectin-1: A link between tumor hypoxia and tumor immune privilege
, 2005
The unfolded protein response: A novel component of the hypoxic stress response in tumors
, 2005
Identification of hypoxia
, 2004
XBP1 is essential for survival under hypoxic conditions and is required for tumor growth
, 2004
Phase I study of stereotactic radiosurgery in patients with locally advanced pancreatic cancer
, 2004
Pancreatic tumors show high levels of hypoxia
, 2000
Loss of PTEN facilitates HIF-1-mediated gene expression
, 2000
Candidate genes for the hypoxic tumor phenotype
, 2000
Stereotactic Body Radiotherapy in the Treatment of Pancreatic Cancer
, 2014
Safety of (90)y radioembolization in patients who have undergone previous external beam radiation
, 2013
A novel aldehyde dehydrogenase-3 activator
, 2013
Seventh Edition (2010) of the AJCC
, 2013
Dosimetric analysis of organs at risk during expiratory gating
, 2013
Chemoradiotherapy Before and After Surgery for Locally Advanced Esophageal Cancer
Metabolic Tumor Volume Predicts Disease Progression
, 2013
Normal Tissue Complication Probability Modeling of Acute Hematologic Toxicity
, 2012
Postchemoradiotherapy Positron Emission Tomography Predicts Pathologic Response
, 2012
Intrafraction Verification of Gated RapidArc by Using Beam-Level Kilovoltage X-Ray Images
, 2012
Positron Emission Tomography for Predicting Pathologic Response After Neoadjuvant Chemoradiotherapy
, 2012
Clinicopathologic and molecular features of sporadic early-onset colorectal adenocarcinoma
, 2012
A novel epidermal growth factor receptor variant lacking multiple domains directly activates
, 2012
Orthovoltage Intraoperative Radiotherapy for Locally Advanced and Recurrent Colorectal Cancer
, 2012
Evaluation of the geometric accuracy of surrogate
, 2012
BRAF-mutated, Microsatellite-stable Adenocarcinoma of the Proximal Colon
, 2012
Intensity-Modulated Radiotherapy for Pancreatic Adenocarcinoma
, 2012
Quantitation of Human Papillomavirus DNA in Plasma of Oropharyngeal Carcinoma Patients
, 2012
Modern Radiation Therapy Techniques for Pancreatic Cancer
, 2012
Antiangiogenic and Radiation Therapy Early Effects on In Vivo Computed Tomography Perfusion
, 2012
A Novel Aldehyde Dehydrogenase-3 Activator Leads to Adult Salivary Stem Cell Enrichment In Vivo
, 2011
Stereotactic Body Radiotherapy for Colorectal Liver Metastases A Pooled Analysis
, 2011
Intensity-Modulated Radiation Therapy Versus Conventional Radiation Therapy for Squamous Cell
, 2011
Tumor Galectin-1 Mediates Tumor Growth and Metastasis through Regulation of T-Cell Apoptosis
, 2011
Unfolded Protein Response Regulation in Keloid Cells
, 2011
Rectal and bladder deformation and displacement during preoperative radiotherapy for rectal cancer
, 2011
Stereotactic Body Radiation Therapy for Gastrointestinal Malignancies
, 2011
A DOSIMETRIC MODEL OF DUODENAL TOXICITY AFTER STEREOTACTIC BODY RADIOTHERAPY FOR PANCREATIC CANCER
, 2010
Expression of p16(INK4A) But Not Hypoxia Markers or Poly Adenosine Diphosphate
, 2010
Orthovoltage intraoperative radiation therapy for pancreatic adenocarcinoma
, 2010
Comparison of Intensity-Modulated Radiotherapy
, 2010
(18)FLUORODEOXYGLUCOSE PET IS PROGNOSTIC OF PROGRESSION
, 2010
Pathological response after chemoradiation for T3 rectal cancer
, 2010
Pathological response after chemoradiation for T3 rectal cancer.
, 2010
Cetuximab-Based Immunotherapy and Radioimmunotherapy of Head and Neck Squamous Cell Carcinoma
, 2010
Circulating miR-210 as a Novel Hypoxia Marker in Pancreatic Cancer
, 2010
The RGD Domain of Human Osteopontin Promotes Tumor Growth
, 2010
EUS-guided gold fiducial insertion for image-guided radiation therapy of pancreatic cancer
, 2010
INTERFRACTIONAL UNCERTAINTY IN THE TREATMENT OF PANCREATIC CANCER WITH RADIATION
, 2010
Multimodality treatment with intensity modulated radiation therapy for esophageal cancer
, 2010
Identification of a biomarker panel using a multiplex proximity ligation
, 2009
Re: The safety and efficacy of robotic image-guided radiosurgery system treatment for intra
, 2009
Oxygen Consumption Can Regulate the Growth of Tumors, a New Perspective on the Warburg Effect
, 2009
Pancreatic Tumor Motion on a Single Planning 4D
, 2009
Treatment of Esophageal Cancer Based on Histology A Surveillance Epidemiology
, 2009
A Primer on Image-guided Radiation Therapy for the Interventional Radiologist
, 2009
Impaired interferon signaling is a common immune defect in human cancer
, 2009
THE RELATIONSHIP BETWEEN HUMAN PAPILLOMAVIRUS STATUS AND OTHER MOLECULAR PROGNOSTIC MARKERS
, 2009
Detection of Solitary Humeral Metastasis From Pancreatic Adenocarcinoma With F-18 FDG PET/CT
, 2009
Safety and Efficacy of Percutaneous Fiducial Marker Implantation for Image-guided Radiation Therapy
, 2009
Gemcitabine chemotherapy
, 2008
In vivo H-1 magnetic resonance spectroscopy of lactate in patients with Stage IV head
, 2008
High-dose single-fraction radiotherapy: Exploiting a new biology?
, 2008
Molecular Imaging of Hypoxia-Inducible Factor 1 alpha and von Hippel-Lindau Interaction in Mice
, 2008
Reducing respiratory motion artifacts in radionuclide imaging through retrospective stacking
, 2008
Initial evaluation of F-18-fluorothymidine (FLT) PET/CT scanning for primary pancreatic cancer
, 2008
Multiplexed proximity ligation assays to profile putative plasma biomarkers
, 2008
Automated contour mapping with a regional deformable model
, 2008
Tissue effects after stereotactic body radiotherapy using cyberknife
, 2008
Preoperative versus postoperative radiotherapy for locally advanced gastroesophageal junction
, 2008
Enhanced 4D cone-beam CT with inter-phase motion model
, 2007
Expression and prognostic significance of a panel of tissue hypoxia markers in head-and
, 2007
Quantitative PET of EGFR expression in xenograft-bearing mice using Cu-64-labeled cetuximab
, 2007
Evaluation of patterns of failure
, 2007
Impact of integrated PET/CT on variability of target volume delineation in rectal cancer
, 2007
Stereotactic body radiotherapy for unresectable pancreatic cancer
, 2007
Plasma osteopontin is an independent prognostic marker for head and neck cancers
, 2006
Results of a phase I dose-escalation study using single
, 2006
Four-dimensional cone-beam computed tomography using an on-board imager
, 2006
Reducing respiratory motion artifacts
, 2006
Targeting XBP-1 as a novel anti-cancer strategy
, 2006
Overview of image-guided radiation therapy
, 2006
Mature results from a randomized phase II trial of cisplatin plus 5
, 2006
An evaluation of tumor oxygenation
, 2006
Identification of mitogen
, 2005
Radiation dose reduction in four-dimensional computed tomography
, 2005
Phase II study to assess the efficacy of conventionally fractionated radiotherapy followed by a
, 2005
Hypoxia upregulates osteopontin expression in NIH-3T3 cells via a ras-activated enhancer
, 2005
A noninvasive approach for assessing tumor hypoxia in xenografts
, 2005
Sample classification from protein mass spectrometry, by 'peak probability contrasts'
, 2004
Phase II double-blind r
, 2004
The use of plasma surface-enhanced laser desorption
, 2004
Identification of hypoxia regulated proteins
, 2004
Improved local control with stereotactic radiosurgical boost
, 2003
Comparison of the comet assay
, 2003
Phase II trial of preoperative 3D conformal radiotherapy, protracted venous infusion 5-fluorouracil
, 2003
Identification of osteopontin as a prognostic plasma marker for head
, 2003
Estimating DNA repair by sequential evaluation of head
, 2002
Epigenetic regulation of gene expression in cervical cancer cells by the tumor microenvironment
, 2000
HYPOXIC ACTIVATION OF NUCLEAR FACTOR-KAPPA
, 1994
MODULATION OF POTASSIUM CHANNELS BY PROTEIN-TYROSINE KINASE INHIBITORS
, 1994
ACTIVATORS OF PROTEIN-KINASE
, 1994
ANALYSIS OF HSF-1 PHOSPHORYLATION IN A549 CELLS TREATED WITH A VARIETY OF STRESSES
, 1994
THE REGULATION OF GRP78 AND MESSENGER-RNA LEVELS BY HYPOXIA IS MODULATED BY PROTEIN
, 1994
HYPOXIA CAUSES THE ACTIVATION OF NUCLEAR FACTOR KAPPA-B THROUGH THE PHOSPHORYLATION OF I
, 1994
INCREASED CYTOTOXICITY OF CHRONIC HYPOXIC CELLS BY MOLECULAR INHIBITION OF GRP78 INDUCTION
, 1994
ACTIVATION OF POTASSIUM CHANNELS BY HYPOXIA AND REOXYGENATION IN THE HUMAN LUNG ADENOCARCINOMA CELL
, 1993
POTASSIUM-CHANNEL ACTIVATION IN RESPONSE TO LOW
, 1993
ACTIVATION OF THE HEAT-SHOCK TRANSCRIPTION FACTOR BY HYPOXIA IN NORMAL AND TUMOR
, 1992
THE INFLUENCE OF CHRONIC ANEMIA ON THE RADIOSENSITIVITY OF 2 MOUSE-TUMORS
What is Dr. Koong's NPI number?An National Provider Identifier (NPI) is a unique ID number that identifies doctors and healthcare providers nationwide.
Dr. Koong's National Provider Identifier (NPI) number is 1598803512.
What common questions do patients ask about Dr. Koong?
Here are answers to patients Frequently Asked Questions (FAQ’s) about Dr. Koong
What is Dr. Albert Koong's specialty?
Dr. Koong is a Radiation Oncologist near Houston, TX.
What does a Radiation Oncologist do?
A radiological oncologist specializes in the therapeutic applications of radiant energy and its modifiers. They focus on the study and management of diseases, particularly malignant tumors.
Is this Dr. Albert Koong affiliated with a ranked Castle Connolly Top Hospital?
Yes, Dr. Koong is affiliated with The University Of Texas Md Anderson Cancer Center which is a Castle Connolly Top Hospital. Castle Connolly Top Hospitals are healthcare institutions recognized for their excellence in specific medical procedures and overall patient care. They are identified through a rigorous peer nomination process, evaluating factors like patient outcomes, quality of care, and expertise. The list recognizes hospitals that excel in 20 or more specific medical procedures, representing the top 25% nationwide. Castle Connolly Top Hospitals
When to see a Radiation Oncologist?: Guides for symptoms, conditions, and treatments
Understand your symptoms and know when it’s time to see a Radiation Oncologist. Explore insights from trusted medical experts on EverydayHealth.com, where you'll find the most relevant content and helpful condition guides for up-to date information about symptoms, causes, diagnosis, treatment and more. See all our health guides to find trusted information on medical conditions from our experts at Everyday Health.
Is Albert Koong accepting new patients in Houston, TX?
Yes, Dr. Albert Koong is accepting new patients at this time.
Does Dr. Albert Koong offer online booking?
Please contact Dr. Koong's office at (713) 792-6161 for information about online booking, telehealth, or to schedule an appointment.
How can I make an appointment with Albert Koong?
Please contact Dr. Koong's office at (713) 792-6161 for information regarding telehealth appointment availability or for scheduling assistance.
Which board certifications does Dr. Albert Koong have?
Dr. Albert Koong is certified by the American Board of Radiology.
Other Radiation Oncologist Near Houston, TX
Radiation Oncologist
Accepting patientsTherapeutic Radiologist
Accepting patientsRadiation Oncologist
Accepting patients